Update on biomarkers of PSP and CBD скачать в хорошем качестве

Update on biomarkers of PSP and CBD

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are progressive neurodegenerative conditions that are yet uncurable and challenging to diagnose. Rodolfo Savica, MD, PhD, Mayo Clinic, Rochester, MN, shares an update on biomarkers of PSP and CBD. Currently, available biomarkers are clinical biomarkers that can support the diagnosis and, to some extent, inform disease progression. However, newer promising biomarkers are under development, including biomarkers measured in the cerebrospinal fluid and serum. The development of novel biomarkers will improve antemortem diagnostic accuracy and may help identify and distinguish different disease phenotypes. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.